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Abstract
Background: Recent studies suggest potential roles of the endocannabinoid system in gastrointestinal inflammation.
Although cannabinoid CB2 receptor expression is increased in inflammatory disorders, the presence and function of the
remaining proteins of the endocannabinoid system in the colonic tissue is not well characterized.
Methodology: Cannabinoid CB1 and CB2 receptors, the enzymes for endocannabinoid biosynthesis DAGLa, DAGLb and
NAPE-PLD, and the endocannabinoid-degradating enzymes FAAH and MAGL were analysed in both acute untreated active
ulcerative pancolitis and treated quiescent patients in comparison with healthy human colonic tissue by immunocyto-
chemistry. Analyses were carried out according to clinical criteria, taking into account the severity at onset and treatment
received.
Principal Findings: Western blot and immunocytochemistry indicated that the endocannabinoid system is present in the
colonic tissue, but it shows a differential distribution in epithelium, lamina propria, smooth muscle and enteric plexi.
Quantification of epithelial immunoreactivity showed an increase of CB2 receptor, DAGLa and MAGL expression, mainly in
mild and moderate pancolitis patients. In contrast, NAPE-PLD expression decreased in moderate and severe pancolitis
patients. During quiescent pancolitis, CB1,C B 2 and DAGLa expression dropped, while NAPE-PLD expression rose, mainly in
patients treated with 5-ASA or 5-ASA+corticosteroids. The number of immune cells containing MAGL and FAAH in the
lamina propria increased in acute pancolitis patients, but dropped after treatment.
Conclusions: Endocannabinoids signaling pathway, through CB2 receptor, may reduce colitis-associated inflammation
suggesting a potential drugable target for the treatment of inflammatory bowel diseases.
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Introduction
The endocannabinoid system (ECS) has been described in the
gastrointestinal tract in the epithelial, immune and neural
compartments. It is involved in many physiological and physio-
pathological actions (peristalsis/contraction, secretion, gastric
emptying, emesis, satiety and immunomodulation/inflammation
and pain).[1–6] ECS roles comprise main facets of the pathogenesis
of Inflammatory Bowel Disease (IBD) in humans, a disease that is
likely to result from multiple factors, especially a disregulation of
intestinal immune system and an inappropriate response to
comensal bacteria or other luminal antigens.[7–9]
ComponentsofECSincludecannabinoidCB1andCB2receptors,
their endogenous lipid ligands (2-arachidony glycerol–2-AG;
anandamide - AEA) and enzymes involved in their biosynthesis
and release (DAGLa and DAGLb for 2-AG; NAPE-PLD for
AEA)[10–15], as well as mechanisms for cellular uptake and
degradation, such as fatty acid amide hydrolase (FAAH) for AEA
and monoacylglycerol lipase (MAGL) for 2-AG.[16,17] The role of
endocannabinoids and its derivatives in IBD is not completely
known[18–22], although cannabinoid CB1 receptors have been
proposed to participate in the epithelial wound healing during
intestinal inflammation.[1–4,20] Additionally, cannabinoid CB2
receptors are expressed in intestinal lamina propria suggesting a
role in immunomodulation.[19,20,22]
Data from animal model and human studies have suggested an
upregulation of the ECS in inflammation processes either by increased
receptor expression or by an enhancement of endocannabinoid
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inhibitors of endocannabinoid membrane transport, or genetic
ablation of FAAH reduced inflammation.[23,25,28] Additionally,
cannabinoid CB2 agonists cause inhibition of proinflammatory
citokines such as tumoral necrosis factor alfa (TNFa) and IL8.[29]
Thus, ECS is positioned to exert a protective role in many of the points
where homeostasis breaks in IBD, although this antiinflammatory role
of the ECS remains to be conclusively determined in humans.[25,30]
The aim of the present study is to analyse, by immunocytochem-
istry, the expression of components of the endocannabinoid system
such as cannabinoid CB1 and CB2 receptors and the enzymes
involved in cannabinoid degradation (FAAH and MAGL) and
biosynthesis (DAGLa, DAGLb and NAPE-PLD), in normal human
colonic tissue in comparison with untreated active ulcerative
pancolitis at disease onset and after achieving remission, according
to clinic and endoscopic criteria, and depending on severity of flare
and treatment received.
Methods
Ethics statement
Biopsies and colonic resection samples were obtained after a
written inform consent from all the patients, as requested by the
clinical guides of Hospital del Mar. Research procedures were
approved by the Hospital del Mar Clinical Research and Ethics
Committee and were conducted according to the principles
expressed in the Declaration of Helsinki.
Subjects
Human colonic endoscopic biopsies were selected from 24 patients
with a first ever flare of extensive Ulcerative Colitis (UC) diagnosed by
clinical, endoscopic and pathological criteria (E3, Montreal classifica-
tion).[31] In each patient rectal mucosal samples were obtained at
onset, at first colonoscopy, before any treatment (acute group) and
after achieving clinical (Truelove and Witts score ,6 points)[32] and
endoscopic remission (Mayo clinic score 0)[33], (quiescent group).
Twenty-two rectal samples were removed from colonic tissue of
patients underwent colonic resections for colorectal cancer, at least
10 cm from the tumour (control group). In the control group, we
confirmed histopathologically the absence of microscopic alter-
ations. The analysis of the immunostaining patterns was carried
out at transmural planes of the normal colonic tissue by comparing
it with H&E staining.
Colonic samples were retrieved from tissue bank of Pathology
Service at the Hospital del Mar from Barcelona, Spain. Data from
each patient were collected retrospectively from medical records
including age, sex, smoke and alcohol history, Body Mass Index
(BMI) and comorbidity. In UC patients we recorded date of
diagnosis, disease location (Montreal classification), endoscopic
(Mayo clinic score) and clinical score (Truelove and Witts score:
mild, moderate and severe) at onset, histological features and
treatments received since initial diagnostic (5-aminosalicilates (5-
ASA); corticosteroids; and/or the immunomodulators (Cyclospor-
ineA and/or Azathioprine). Table 1 shows some of these records
that characterize each UC patients.
Immunohistochemistry
We analyzed the distribution of CB1 and CB2 receptors, FAAH,
MAGL, DAGLa, DAGLb, and NAPE-PLD in the normal colonic
tissue and in the acute and quiescent UC mucosa by immuno-
histochemistry, following methods previously described[34,35].
Tissue blocks were fixed in 4% (w/v) buffered formaldehyde and
embedded in paraffin. Blocks were cut into longitudinal 5-mm-
thick sections using a Microm HM325 microtome (MICROM,
Walldorf, Germany). Sections were mounted on glass slides with
the positively charged surface (DAKO Real, ref. S2024, Glostrup,
Germany) and air-dried. After the sections were dewaxed, antigen
retrieval was achieved through incubating in H2Od containing
50 mM sodium citrate (pH 9) for 15 minutes at 80uC, followed by
washes in 0,1M phosphate-buffered saline (PBS; pH 7.4). Then
incubation in 3% hydrogen peroxide (H2O2) for 20 minutes was
achieved to inactivate the endogenous peroxidase. Later, sections
were blocked in 10% donkey serum in PBS and 0.1% NaN3 for
1 hour, and incubated overnight at room temperature with the
following antibodies34: anti-CB1 receptor (diluted 1:100; ABR,
cat. no. PA1-745, lot. no. 424-121); anti-CB2 receptor (diluted
1:100; ABR, cat. no. PA1-746A, lot. no. 452-114); anti-FAAH
(diluted 1:100; Cayman, cat. no. 101600, lot. no. 157878); anti-
MAGL (diluted 1:100; Cayman, cat. no. 100035, lot. no. 163084);
anti-NAPE-PLD, diluted 1:100; anti-DAGLa, diluted 1:50; and
anti-DAGLb, diluted 1:50 (supporting information S1). Then, the
sections were incubated in a biotinylated donkey anti-rabbit
immunoglobulin (Amersham) diluted 1:500 for 1 hour, and
incubated in ExtrAvidin peroxidase (Sigma) diluted 1:2000 for
1 hour. We revealed immunolabeling with 0.05% diaminobenzi-
dine (DAB; Sigma), 0.05% nickel ammonium sulphate, and 0.03%
H2O2 in PBS. Al steps were carried out in PBS with gently
agitation at room temperature. Sections were dehydrated in
ethanol, cleared in xylene, and coverslipped with Eukitt mounting
medium (Kindler GmBH and Co., Freiburg, Germany).
Digital high-resolution microphotographs were taken under the
same conditions of light and brightness/contrast by an Olympus
BX41 microscope equipped with an Olympus DP70 digital
camera (Olympus Europa GmbH, Hamburg, Germany). Digital
images were mounted and labelled using Adobe PageMaker (San
Jose, CA, USA).
Western blotting
We collected prospectively 8 rectal samples of control patients
underwent colonic resection biopsies, processed as previously
described [34,35], to evaluated the presence of CB1 and CB2
receptors, FAAH, MAGL, DAGLa, DAGLb and NAPE-PLD by
Western blotting. Samples from were immediately snap frozen in
liquid nitrogen and stored at 280uC until use. Membrane extracts
of colon tissue were prepared in HEPES 50 mM (pH 8)-sucrose
0.32 M buffer by using a homogenizer. The homogenate was
centrifuged at 800 xg for 10 minutes at 4uC and the supernatant
was centrifuged at 40000 xg for 30 minutes. The pellet was
suspended in HEPES 50 mM buffer and potterized using a
homogenizer.
For immunoblotting, equivalent amounts of membrane proteins
(20 mg) were separated by 10% sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE), electroblotted
onto nitrocellulose membranes, and controlled by Ponceau red
staining. Blots were preincubated with a blocking buffer
containing PBS, 0.1% Tween 20 and 2% albumin fraction V
from bovine serum (Merck, Whitehouse Station, NJ, USA) for 1 h
at room temperature. For protein detection, each blotted
membrane lane was incubated separately with the specific CB1
(1:250), CB2 (1:300), FAAH (1:200), MAGL (1:200), DA-
GLa(1:200), DAGLb (1:200) and NAPE-PLD (1:100) antibodies,
diluted in the blocking buffer, overnight at 4uC. After extensive
washing in PBS containing 1% Tween 20 (PBS-T), a peroxydase-
conjugated goat anti-rabbit antibody (Promega, Madison, WI,
USA) was added (1:10000) for 1 h at room temperature.
Biotinylated marker proteins with defined molecular weights were
used for molecular weight determination in Western blots (ECL
TM
Western Blotting Molecular Weight Markers, Amersham/GE
Cannabinoids and Colitis
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repeated washing in PBS-T and the specific protein bands were
visualized using the enhanced chemiluminiscence technique (ECL,
Amersham) and Auto-Biochemi
TM Imaging System (LTF
Labortechnik GmbH, Wasserburg/Bodensee, Germany). Western
Blots showed that each primary antibody detects a protein of the
expected molecular size.
As controls, we incubated blotted membrane lanes with the
primary antibody preadsorbed with the immunizing peptides
(Table 2): CB1 and CB2 (both at 20 mg/ml; kindly donated by Dr.
K. Mackie), FAAH (10 mg/ml; Cayman, lot. no. 301600), MAGL
(5 mg/ml; Cayman, lot. no. 300014), DAGLa, DAGLb and
NAPE-PLD (25 mg/ml, 100 mg/ml and 25 mg/ml respectively;
JPT, Berlin, Germany). We did not detect staining under these
conditions.
Quantification of mucosa immunostaining
One immunostaining batch contained 70 tissue sections of all
experimental groups, thus slices corresponding to the three
experimental groups were stained simultaneously. For each primary
antibody and for each subject, 2–3 different batches were run. On
each tissue section we focussed on epithelium and lamina propria of
the mucosa. For epithelium, we carried out a densitometrical
quantification for each component of the ECS. For lamina propria,
we evaluated the type and the number of immunostained immune
cells for each 100 cells observed by hematoxylin-eosin (H&E)
staining. In addition, ECS quantification was segregated depending
on UC severity scored to mild, moderate and severe (Truelove and
Witts score), and by the treatment received (5-ASA, corticosteroids,
and/or the immunomodulators).
Digital high-resolution microphotographs were taken with the
106objective of an Olympus BX41 microscope under the same
Table 1. Clinical characteristics of UC patients
1.
Patient UC Nu Age Sex Smoker BMI Clinic Score Endosc. Score Histol. Score UC Treatment
1 35 W No 24,97 Moderate 2 Mild 5-ASA + cortic
2 29 W No 26,1 Moderate 2 Moderate-Severe 5-ASA + cortic + IMM
3 29 M 15 cig/day 21,88 Severe 3 Moderate 5-ASA + cortic + IMM
4 28 M Smoker 30,86 Moderate 2 Moderate 5-ASA + cortic
5 46 M 30 cig/day 28 Moderate 3 Severe 5- ASA + cortic
6 38 W No 23,87 Mild 1 Severe 5-ASA
7 69 M Ex-smoker 22 Mild 1 Mild 5-ASA + cortic
8 20 M No 22,98 Severe 2 Mild 5-ASA + cortic + IMM
9 23 M No 25,01 Moderate 2 Moderate 5-ASA + cortic + IMM
10 26 W 6 cig/day 23,42 Severe 3 Moderate-Severe 5-ASA + cortic
11 37 M No 22 Mild 1 Mild 5-ASA
12 48 M No 21,24 Moderate 2 Severe 5-ASA + cortic
13 34 M Ex-smoker 22,86 Severe 2 Severe 5-ASA + cortic
14 61 M Ex-smoker 23,26 Severe 2 Mild-moderate 5-ASA + cortic
15 28 W No 23,05 Mild 2 Moderate 5-ASA
16 26 M No 24,3 Moderate 2 Mild 5-ASA + cortic
17 39 M No 22,52 Moderate 2 Mild 5-ASA + cortic
18 17 M Smoker 22,53 Moderate 2 Severe 5-ASA + cortic
19 62 M 4 cig/day 25,27 Moderate 3 Mild 5-ASA + cortic
20 30 M No 22,86 Moderate 2 Severe Cortic + AZA
21 42 W No 27,34 Mild 2 Severe 5-ASA + cortic
22 73 M 20 cig/day 26,95 Moderate 2 Mild 5-ASA + cortic
23 44 M Ex-smoker 23,98 Moderate 2 Severe 5-ASA + cortic + IMM
24 62 W No 24,22 Mild 2 Moderate 5-ASA + cortic
1Data from each patient were collected retrospectively from medical records including age, sex, smoke history, Body Index Mass (BMI), endoscopic (Mayo clinic score)
and clinical score (Truelove and Witts score: mild, moderate and severe) at onset, histological features and treatments received since initial diagnostic (5-aminosali-
cilates, 5-ASA; corticosteroids; and/or the immunomodulators, IMM, Cyclosporine A and/or Azathioprine).
doi:10.1371/journal.pone.0006893.t001
Table 2. Immunizing peptides used in this study.
Proteins Peptides sequences GenPept accession number
CB1 MKSILDGLADTTFRTIT
TDLLYVGSNDIQYEDIK
GDMASKLGYFPQKFPLT
SFRGSPFQEKMTA
GDNSPLVPAGDTT
NP_036916.1
CB2 MAGCRELELTNGSNGG
LEFNPMKEYMILSDAQ
NP_065418.2
NAPE-PLD MDENSCDKAFEET NP_955413.1
DAGLa CGASPTKQDDLVISAR NP_001005886.1
DAGLb SSDSPLDSPTKYPTLC NP_001100590.1
FAAH CLRFMREVEQLMTPQKQPS NP_077046.1
MAGL SSPRRTPQNVPYQDL Q8R431.1
doi:10.1371/journal.pone.0006893.t002
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immunostaining was carried out by measuring densitometry of the
selected areas using the analysis software ImageJ 1,386 (Ras-
band,W.S., ImageJ, National Institute of Health, Bethesda,
Maryland, USA).
Statistical analysis
Data were analyzed using SPSS 15.0 software (Statistical
Package for the Social Sciences Inc., Chicago, Illinois, USA).
Results are expressed as mean6SEM. Differences between groups
were evaluated using U Mann Witney and Wilcoxon tests for non
parametric observations. A P value of P,0.05 was considered
statistically significant.
Results
Presence of the endocannabinoid system in the normal
human colonic tissue: Western blot analysis
Western blot analysis of membrane proteins from normal
human colon tissue revealed the presence of all ECS proteins
studied. They appeared as prominent bands of 53 kD for CB1,
(fig. 1, lane 1), 50 kD for CB2 (fig. 1, lane 3), 35 kD for MAGL
(fig. 1, lane 5), 120 and 73 kD for DAGLa and DAGLb
respectively (fig. 1, lanes 7 and 9), and 46 and 63 kD for NAPE-
PLD and FAAH respectively (fig. 1, lanes 11 and 13). In each case,
the immunoreactive bands were abolished after adsorption with
the immunizing peptides (fig. 1, lanes 2, 4, 6, 8, 10, 12, 14).
Immunohistochemical distribution of the
endocannabinoid system in the normal human colonic
tissue
Results for the immunohistochemical distribution were summa-
rized in a rating scale (Table 3). Intense CB1 immunoreactivity is
showed in the epithelial cells of the crypts (C), being prominent in
the absorptive cells, mainly on the apical surface facing the lumen
(fig. 2D, E, arrows). We observe CB1 immunoreactivity in some
plasma cells of the lamina propria (LP; fig. 2E, inset). A low/
moderate staining was detected in the muscularis mucosae (MM),
including the smooth muscle of the blood vessels, but intensely
staining characterized inner circular (CSM) and outer longitudinal
(LSM)smoothmusclelayers(fig.2D,F).Ofnote,thevaricoseaspect
ofCB1 immunoreactivityonthe muscle cellsthatprobablyconsist of
nerve terminals (fig. 2F, inset). We observed faintly immunostaining
in the parasympathetic nervous cells of both Meisnner’s and
myenteric plexi (MP), except of some scattered fibers (fig. 2F). Some
CB1+ connective cells were also detected in the serosa layer.
CB2 immunoreactivity was detected in the colonic epithelium of
both absorptive and goblet cells (fig. 2H). Of note, a stronger CB2
Figure 1. Western blots of membrane extracts from human colonic tissue. They showed prominent immunoreactive bands of the expected
size for the ECS proteins. See text. Positions of molecular markers (MW) are indicated at the left.
doi:10.1371/journal.pone.0006893.g001
Table 3. Immunoreactivity of endocannabinoid system in normal colonic tissue (n=22)
1.
Epithelium Glands Lamina propria Smooth muscle Myenteric plexus
CB1 +++ 2 ++ 2
CB2 +++ + + ++++
FAAH ++ ++ 2 ++++
MAGL ++ ++ 2 ++
NAPE-PLD +++ ++ +++ 2
DAGLa +++ ++ ++++ ++
DAGLb ++++ ++ +++ ++++
1Gray-scale values measured in single epithelium, lamina propria, muscular layers and plexi are represented on an arbitrary rating scale of the immunoreactivity of each
structure. Symbols are as follows: very high (++++), high (+++), low (++), very low (+) and without immunoreactivity (2).
doi:10.1371/journal.pone.0006893.t003
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PLoS ONE | www.plosone.org 4 September 2009 | Volume 4 | Issue 9 | e6893Figure 2. Immunohistochemistry for CB1 and CB2 receptors, FAAH and MAGL in human colonic tissue. Morphology of normal human
colon, stained with H&E (A–C). General views of transmural sections through the colon (A, D, G, J, M). High-magnification photomicrographs of the
colonic epithelium and lamina propria (B, E, H, K, N), smooth muscle and myenteric plexus (C, F, I, L, O). Abbreviations: C, crypt; CSM, circular smooth
muscle; LP, lamina propria; LSM, longitudinal smooth muscle; M, mucosa; MM, muscularis mucosae, MP, myenteric plexus; SM, submucosa.
doi:10.1371/journal.pone.0006893.g002
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than in the remaining colonic epithelium (fig. 2G inset). A number
of subepithelial CB2+ plasma cells and probably some macro-
phages were detected in the lamina propria (fig. 2H arrow, inset).
We also observed weak CB2 immunoreactivity in the muscularis
mucosae and muscularis externa whereas intense staining was
located in the endothelial cells of the blood vessels (fig. 2I arrow,
inset). Numerous CB2+ ganglion cells and fibers were evident in
the myenteric plexus (fig. 2I) and the submucosal plexi.
FAAH immunostaining disposed in the epithelial cells, being
prominent in the apical one third and perinuclear portions of the
absorptive cells (fig. 2J, K inset, asterisk). The brush border of the
microvilli was nearly absent of staining (fig. 2K inset, arrowheads).
We detected few scattered FAAH+ immune plasma cells in the
lamina propria. No staining was observed neither in the
muscularis mucosae, muscularis externa or serosa, whereas intense
staining was observed in some ganglion cells and fibers of the
myenteric plexus (fig. 2L).
MAGL immunoreactivity was located in the central portion of
the epithelial cells, thus, apical to the nucleus of the absorptive cells
and basal to the mucus droplets of the goblet cells (fig. 2M, N, inset
n0). A number of immunoreactive polymorphonuclear cells was
distinguished in the lamina propria (fig. 2N, inset n9). No staining
was detected in both muscularis mucosae and externa. The
myenteric plexus was characterized by a meshwork of MAGL+
fibers that disposed surrounding unstained parasympathetic
nervous cells (fig. 2O).
Strong NAPE-PLD immunoreactivity in the apical surface of
the epithelial border of the crypts (fig. 3A) and numerous positive
plasma cells was observed (fig. 3B, inset). Intense NAPE-PLD
immunostaining characterized both layers of muscularis externa
(fig. 3C). Numerous immunoreactive fibers, but not cell bodies,
disposed in the myenteric plexus (fig. 3C).
We observed a similar DAGLa staining pattern in the colonic
tissue to that of CB1 and NAPE-PLD proteins (fig. 3D). An intense
immunoreactivity characterized the apical surface of epithelial
border facing to lumen (arrows in fig. 3E, inset e9). We observed
some DAGLa+ plasma cells in the lamina propria (fig. 3E, inset
e0). Muscularis mucosae and externa showed an intense DAGLa
immunoreactivity (fig. 3F) in a similar granular aspect to that of
CB1 immunoreactivity. Numerous DAGLa+ fibers disposed
surrounding unstained ganglion cells in the myenteric plexus
(fig. 3F, inset).
Intense DAGLb expression was mainly located surrounding the
nucleus of the epithelial cells (fig. 3G, H, inset h0). A number of
scattered plasma cells also showed intense DAGLb staining
Figure 3. Immunohistochemistry for NAPE-PLD, DAGLa and DAGLb in human colonic tissue. General views of transmural sections
through the colon (A, D, G). High-magnification photomicrographs of the colonic epithelium and lamina propria (B, E, H), smooth muscle and
myenteric plexus (C, F, I).
doi:10.1371/journal.pone.0006893.g003
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strongly DAGLb expression was evident in both layers of the
muscularis externa, mainly in the inner one (fig. 3I). The
myenteric plexus was characterized by strongly DAGLb+ ganglion
cells and a dense fibre network (fig. 3I).
Densitometrical quantification of ECS immunoreactivity
in the colonic epithelium
Microphotographs showing qualitative differences of the
immunoreactivity for each ECS component in the epithelium of
control, acute and quiescent groups are shown in figure 4.
Quantification of epithelial immunoreactivity for ECS compo-
nents is shown in figure 5. CB1 expression was maintained in acute
group [49.1861.44 vs 49. 3761.62 (610
3)] but, in quiescent group,
was lower than in control one [44.7561.22 vs 49.1861.44 (610
3);
p,0.001], as well as when was compared with the acute one
[44.7561.22 vs 49.3761.62 (610
3); p,0.01], suggesting that CB1
receptor may be downregulated by the treatment. We detected an
increase of CB2 expression in acute group comparing with the
control one [61.0962.54 vs 53.3061.27 (610
3); p,0.01]. In
contrast, increased CB2 expression was reversed in quiescent group
[61.0962.54 vs 55.1561.69 (610
3); p,0.01]. These data may
indicate an overexpression of CB2 receptor during the acute
inflammation but, once controlled by the treatment, restored to
basal levels. However, the increased ratio in acute samples was due
to an increase of CB2 receptors [1.2260.04 vs 1.0660.02; p,0.01]
whereas in quiescent samples it was derived from a downregulation
of CB1 receptors [1.2360.039 vs 1.0660.02; p,0.001].
Enzymes of 2-AG pathway were overexpressed in UC patients;
in acute and quiescent groups in comparison with control one.
DAGLa and MAGL were significantly increased in acute group
regarding control one [62.7963.71 vs 53.7961.29 (610
3) for
DAGLa; 65.8161.99 vs 60.8160.94 (610
3) for MAGL; p,0.05].
However, DAGLa increase in quiescent group did not reach
statistical significance when compared with control group
[58.2262.16 vs 53.7961.29 (610
3); p=0.06]. In contrast, MAGL
increase was statistically maintained between quiescent and
control groups [65.8561.64 vs 60.8160.94 (610
3); p,0.01].
These data suggest an increase of 2-AG turnover during the
inflammation and a decrease after achieving remission. No
statistical differences in DAGLb expression were observed
between control, acute and quiescent groups. However, the
DAGLa+b/MAGL ratio, an estimation of the balance of 2-AG
levels, did not change either in acute or quiescent patients.
NAPE-PLD immunoreactivity was significantly decreased in
acute group in comparison with control one [49.4661.38 vs
54.6361.56 (610
3); p,0.01]. NAPE-PLD expression in quiescent
group recovered to control levels [53.1161.46 vs 54.6361.56
(610
3)], being this increase statistically significant when compared
with acute group [53.1161.46 vs 49.4661.38 (610
3); p,0.01]. No
statistical differences in FAAH expression were found between
control, acute and quiescent groups. The NAPE-PLD/FAAH ratio,
an estimation of AEA balance, decreased in acute group in
comparison with control group (0.9360.02 vs 1.0660.03; p,0.01),
and increased to control levels in quiescent group when was
compared with acute group (0.9960.02 vs 0.9360.02; p,0.05).
These data suggest a dysregulation of the AEA balance in the acute
inflammatory process that recovers to control level after treatment.
Percentage of the ECS immunoreactive cells in the
lamina propria
We found pronounced changes in the number of FAAH+ and
MAGL+ cells, but not to the remaining ECS components (fig. 6).
FAAH+ cell number rose in acute group compared with control
one (11.2%61.9% vs 1.29%60.3%; p,0.001). Besides, a decrease
in the number of FAAH+ cells was evidenced in quiescent group
compared with acute group (4.8%60.6% vs 11.2%61.9%;
p,0.001) but was still notably higher than in controls (p,0.001).
We found higher percentage of MAGL+ cells in acute and
quiescent groups than in controls (4.4%60.5% vs 1.2%60.3%;
3.4%60.5% vs 1.2%60.3%; p,0.001).
Quantification of epithelial ECS immunoreactivity
depending on the severity of the UC disease
We compared ECS in acute group depending on the severity of
the disease and after remission (quiescent group) vs control tissue
(fig. 7). CB1 expression did not change in acute samples at any
clinic score. In quiescent samples, CB1 expression dropped
significantly in moderate UC flare patients [45.4661.91 vs
49.1861.44 (610
3); p,0.05] or severe [42.4861.32 vs
49.1861.44 (610
3); p,0.05], in comparison with controls
(Fig. 6). In mild UC, the decrease did not reach the significance
between quiescent and control groups [44.8960.64 vs 49.1861.44
(610
3); p=0.06].
Intense CB2 immunoreactivity in acute group was evidenced in
mild [70.80167.042 vs 53.30161.278 (610
3); p,0.01] and
moderate colitis [58.8662.46 vs 53.3061.27 (610
3); p,0.05], in
comparison with controls but not in the severe cases. There was no
change in CB2 immunoreactivity between quiescent and control
samples.
We only found a rise of DAGLa expression in acute moderate
colitis compared with control groups [61.2163.20 vs 53.2861.16
(610
3); p,0.05]. In mild colitis patients, higher levels of DAGLa
were also observed in quiescent samples compared with controls
[55.6762.93 vs 53.2861.16 (610
3); p,0.05]. No differences in
DAGLb expression were observed among the three clinic scores.
Regarding NAPE-PLD, no differences were found in mild colitis
among the three groups, but when we compared acute group with
controls as the severity raises the expression drops. Differences
were significant in moderate [49.3760.88 vs 54.6361.56 (610
3);
p,0.05] and severe colitis [45.7060.74 vs 54.6361.56 (610
3);
p,0.01]. NAPE-PLD immunoreactivity rose to control values in
quiescent stage of moderate colitis compared with acute group
[52.3466.68 vs 49.3763.18 (610
3); p,0.05].
Higher levels of FAAH immunoreactivity were measured in
quiescent samples of moderate UC patients compared with acute
[55.7862.15 vs 50.7961.80 (610
3); p,0.05] and control samples
[55.7862.15 vs 51.0161.63 (610
3); p,0.05]. No changes of
FAAH expression were detected in acute or quiescent groups from
mild and severe clinic score patients. In mild and moderate colitis,
we evidenced higher expression of MAGL in acute [64.5761.60 vs
60.0360.72 (610
3) in mild; 67.4163.49 vs 60.0360.72 (610
3)i n
moderate; p,0.05] and quiescent [68.2560.96 vs 60.0360.72
(610
3) in mild; 67.3662.54 vs 60.0360.72 (610
3) in moderate;
p,0.001 and p,0.05 respectively] stages compared with controls.
In mild UC these levels were even higher in quiescent stage than in
acute one (p,0.05). No differences were seen in severe colitis
among the three groups.
Quantification of epithelial ECS immunoreactivity
depending on treatment
We analyzed ECS immunoreactivity in quiescent samples
depending on the treatment received: 5-ASA (3 cases), 5-ASA
and corticosteroids (15 cases), or 5-ASA, corticosteroids and
immunomodulators (6 cases) (fig. 8). Regarding CB1 levels, there
was a decrease in patients treated with 5-ASA+corticosteroids
Cannabinoids and Colitis
PLoS ONE | www.plosone.org 7 September 2009 | Volume 4 | Issue 9 | e6893Figure 4. Immunohistochemistry in human healthy (control), acute UC and quiescent UC colonic tissue. Representative
microphotographs of CB1 receptor (A–C), CB2 receptor (D–F), DAGLa (G–I), DAGLb (J–L), MAGL (M–O), NAPE-PLD (P–R), FAAH (S–V) were shown.
doi:10.1371/journal.pone.0006893.g004
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3); p,0.01] but not with other
treatments. By contrast, CB2 and MAGL expression increased in
5-ASA-treated patients but not after the remaining treatments
[57.2061.87 vs 53.2961.52 (610
3) for CB2; 68.7861.78 vs
60.0360.72 (610
3) for MAGL; p,0.05]. DAGLa, DAGLb,
NAPE-PLD and FAAH expression were not altered by the
treatment.
Discussion
Our data are consistent with previous studies on the expression
of CB1 and CB2 receptors in human and rodent co-
lon.[20,21,36,37] A novelty of our study is the finding of CB1
staining in the goblet cells. Interestingly, the previous human
study[20] did not report CB1 staining in the goblet cells probably
as a result of mucus-blocking antibody binding. Casu and
collaborators[21] described non-specific labelling in the murine
colonic epithelial cells of the large intestine because it persisted in
preabsorption and omission controls. In contrast, we observed
faintly CB1 immunoreactivity in the submucosal and myenteric
ganglion plexi, with the exception of some fibers. The well-
described presynaptic localization of CB1 receptor contrasts with
the presence of this receptor into submucosal ganglion cell bodies,
as was described in the human and mouse colon.[20,21,37] Our
results revealed similar CB2 expression in the mucosal epithelial
cells from normal patient samples in a previous human colonic
study that, using different CB2 antibodies, supports our immuno-
histochemical data.[20] Of note, we observed strong CB2
expression in the Paneth cells at the bottom of the crypts. CB2+
subepithelial plasma cells and macrophages in the lamina propria
was described previously by Wright and collaborators.[20,22] A
novelty data was the finding of CB2 staining in the submucosal and
myenteric plexi of the normal human colonic tissue. Recently, CB2
expression was observed in the enteric nervous system in rodent
and human ileum[19,22], and in the rat ileum containing
longitudinal muscle and myenteric plexus.[38] Taking together
Figure 5. Quantification of ECS component immunoreactivity in the colonic epithelium. A: Untreated acute UC at disease onset showed
increases in CB2, DAGLa and MAGL immunoreactivity, and decreases in NAPE-PLD immunostaining. After achieving remission (quiescence), CB1 and
CB2 receptor immunoreactivity dropped, MAGL immunostaining maintained the same levels than acute group and NAPE-PLD immunoreactivity
reverted to control levels. B:C B 2/CB1 ratio increased in both groups. However, CB2 immunoreactivity increased in acute patients, while in quiescent
patients there was a decrease of CB1 receptor and a reverted restoration of CB2 level. NAPE-PLD/FAAH ratio dropped in acute group, but rose to
control levels in quiescent one. Histograms represent the mean6SEM. U Mann Witney and Wilcoxon tests: *P,0.05, **P,0.01 and ***P,0.001 versus
control group; #P,0.05 and ##P,0.01 versus acute group. N=22, 24 and 24 for control, acute and quiescent groups respectively.
doi:10.1371/journal.pone.0006893.g005
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CB2 receptors in human colonic tissue. CB1 could be modulating
colonic neuronal input and secretion while CB2 may participate in
colonic immunomodulation.
Other important novelty is the presence of the two endocanna-
binoid-degradating enzymes (FAAH and MAGL) in the epithelial
cells of human colonic tissue. We have clearly detected FAAH
expression in plasma cells of the lamina propria and in ganglion
cells of the enteric nervous system. These results are related to the
fact that FAAH blockers like URB597 reduce significantly the
inflammation in the mouse colon[28], and selective FAAH
inhibitors like AA-5-HT inhibited intestinal motility.[39] MAGL
localization into epithelial cells is in agreement with the presence
of MAGL activity in the soluble and membrane cellular
fractions.[40] Of note the immunoreactive polymorphonuclear
cells in the lamina propria, a fact that has not been observed
previously. In contrast to Duncan and collaborators[40], we did
not observed MAGL immunoreactivity in the human smooth
muscle and mucosal layers, but we detected MAGL expression in
fibers of the enteric nervous system.
We have reported the first analysis of the presence of DAGLa,
DAGLb and NAPE-PLD in the human colonic tissue. Although 2-
AG is considered a full cannabinoid receptor agonist, it is also an
intermediate in triacyl/diacylglycerol metabolism as well as a
prominent molecule linking the cannabinoid signalling with
lysophospholipids and diacilglycerol-PKC signalling system. How-
ever, although we cannot strictly consider both DAGLa and
DAGLb as pure endocannabinoid-synthesizing enzymes, we will
focus on their potential role in the endocannabinoid system.
On the other hand, NAPE-PLD is another recently characterized
cannabinoid biosynthesis enzyme that mediates the release of N-
acyl ethanolamides (including AEA) from a phospholipid precursor
(N-acyl-phosphatidylethanolamide, NAPE).[15,41] Our results are
compatible with an active synthesis of ECs, i.e. AEA and 2-AG, in
healthy human colonic tissue.
There are higher levels of cannabinoid CB2 receptors (but not
CB1 receptors) in the mucosa epithelium of UC, mainly in mild
and moderate-scored patients. These data suggest a dysregulat-
e dA E At o n ei nt h ec o l o no ft h e s ep a t i e n t s ,i na g r e e m e n tw i t h
previous findings.[20,25] However, we observed low NAPE-
PLD expression, mainly in moderate and severe-scored panco-
litis patients, and no changes in the AEA-degrading enzyme
FAAH, suggesting a decrease of AEA levels, as deduced by the
NAPE-PLD/FAAH ratio, while D-Argenio et al. found high
AEA levels in biopsy samples of colons from untreated UC
patients.[25] This discrepancy may be explained by the fact that
NAPE-PLD is not the only source for AEA, as others enzymes
are also capable of generating AEA from NAPE, such as a/b
hydrolase 4, lyso-PLD, lyso-PLC, and phosphatases such as
PTPN22.[42–44] Thus, although we detect a dysregulated AEA
tone, the whole changes of AEA-related enzymes could lead to
an increased level of this EC.
Regarding 2-AG, we observed an increase of DAGLa and
MAGL expression in the colonic epithelium of acute UC patients,
suggesting an increase of 2-AG turnover during the inflammation,
but not a dysbalance of 2-AG levels, as suggest the DAGL/MAGL
ratio. The maintenance of DAGL/MAGL ratio is in agreement
with the absence of 2-AG variations observed in the mucosa of
TNBS-treated rats, DNBS-treated mice and UC patients.[25] The
high DAGLa and DAGLb expression detected in the human
colonic epithelium may be partially related with the high 2-AG
levels described in colonic mucosa of untreated rats, in contrast to
that of control patients.[25]
Interestingly, severe clinic score patients showed no significant
increase in CB2 receptors, and this fact correlates with a lack of
increased 2-AG turnover (no increases of synthesizing- and
degrading enzymes), thus suggesting a diminished ECS response
to the inflammatory insult. In light of these findings, we could
speculate that ECS-related drugs potentiating ECs turnover could
be useful in managing the disease in this subpopulation of patients.
Figure 6. Percentage of immunoreactive immune cells for ECS components in the lamina propria. Untreated acute UC at disease onset is
associated with high number of FAAH+ and MAGL+ immune cells that was significantly diminished after treatment only in FAAH immunoreactivity.
Histograms represent the mean6SEM. U Mann Witney and Wilcoxon tests: ***P,0.001 versus control group; ###P,0.001 versus acute group.
N=22, 24 and 24 for control, acute and quiescent groups respectively.
doi:10.1371/journal.pone.0006893.g006
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CB2 increase in UC patients is reverted in the chronic state,
irrespective of the treatment. This fact suggests a putative role of
CB2 receptor in mediating acute inflammatory response. In
addition, the treatments, mainly the 5-ASA+corticosteroids one,
lead to a chronic down-regulation of CB1 receptor (not displayed
acutely), probably reflecting a diminished colonic functionality in
the chronic state of the disease, since CB1 receptor have been
implicated in colonic motility and secretion.[27,39] Thus,
cannabinoid CB1 receptor could be a biological marker of UC
progression. Interestingly, while the high MAGL expression is
maintained in quiescent patients, NAPE-PLD expression recov-
ered to control levels, suggesting a partial recovery of the ECS
dysregulation after treatments.
In summary, these data indicate that endocannabinoid signaling
pathway is altered in UC, acting probably through cannabinoid
Figure 7. Quantification of epithelial ECS immunoreactivity depending on the UC severity score. Main changes were observed mainly in
mild and moderate acute UC. Histograms represent the mean6SEM. U Mann Witney and Wilcoxon tests: *P,0.05, **P,0.01 and ***P,0.001 versus
control group; #P,0.05 versus acute group. N=6, 13 and 5 for mild, moderate and severe groups respectively.
doi:10.1371/journal.pone.0006893.g007
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PLoS ONE | www.plosone.org 11 September 2009 | Volume 4 | Issue 9 | e6893CB2 receptor as a counteregulatory system aimed to reduce colitis-
associated inflammation. In addition, the changes observed in the
remaining ECS components, both acutely and after treatment,
suggest that drugs acting at the ECS could be potential therapeutic
approaches that need to be explored in more depth, for the
treatment of inflammatory bowel diseases.
Supporting Information
Supporting Information S1 Generation of NAPE-PLD-,
DAGLa-, DAGLb-specific antibodies. We have generated poly-
clonal rabbit antibodies against proteins of the cannabinoid
machinery. Immunizing peptides were 1) a 13-amino-acid (aa)
peptide comprising part of both the C-terminal and the N-
terminal regions of NAPE-PLD (MDENSCDKAFEET); 2) a 16-
aa peptide from the C-terminal region of DAGL alpha
(CGASPTKQDDLVISAR); 3) a 16-aa peptide from an internal
sequence of DAGL beta (SSDSPLDSPTKYPTLC). We employed
a chimeric sequence peptide as immunogen for NAPE-PLD
antibody generation. The aim of this chimeric construction was to
obtain two distant epitopes exposed in the native protein because
one of them belongs to the N-terminal and the other to the C-
Figure 8. Quantification of epithelial ECS immunoreactivity depending on the treatment received. As a relevant finding, treatment is
associated with changes in the expression of cannabinoid receptors and EC-production and -degradation enzymes, suggesting that these proteins
can be considered as biomarkers of active disease/response to treatment. Histograms represent the mean6SEM. U Mann Witney and Wilcoxon tests:
*P,0.05 and **P,0.01 versus control group; #P,0.05 versus acute group. N=3, 15 and 6 for 5-ASA, 5-ASA+corticosteroids and 5-
ASA+corticosteroids+immunomodulators respectively.
doi:10.1371/journal.pone.0006893.g008
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PLoS ONE | www.plosone.org 12 September 2009 | Volume 4 | Issue 9 | e6893terminal region of the protein, both regions having random coil
structures. NAPE-PLD, DAGL alpha and DAGL beta peptides
were synthesized and coupled to keyhole limpet hemocyanin
(KLH, JPT Peptide Technologies, Berlin, Germany). The three
peptides were injected to rabbits (two animals per peptides),
according to standard protocols for generation of antisera, with the
IgG fraction subsequently purified by means of a protein A
column (Sigma, St. Louis, MO, USA).
Found at: doi:10.1371/journal.pone.0006893.s001 (0.03 MB
DOC)
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